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Abstract Darbepoetin alfa is a biopharmaceutical glyco-
protein that stimulates erythropoiesis and is used to treat
anemia, which associated with renal failure and cancer
chemotherapy. We herein describe the structural charac-
terization of recombinant darbepoetin alfa produced by
Leishmania tarentolae T7-TR host. The DNA expression
cassette was integrated into the L. tarentolae genome
through homologous recombination. Transformed clones
were selected by antibiotic resistance, diagnostic PCRs,
and protein expression analysis. The structure of recom-
binant darbepoetin alfa was analyzed by isoelectric focus-
ing, ultraviolet–visible spectrum, and circular dichroism
(CD) spectroscopy. Expression analysis showed the pres-
ence of a protein band at 40 kDa, and its expression level
was 51.2 mg/ml of culture medium. Darbepoetin alfa have
5 isoforms with varying degree of sialylation. The UV
absorption and CD spectra were analogous to original drug
(Aranesp), which confirmed that the produced protein was
darbepoetin alfa. Potency test results revealed that the
purified protein was biologically active. In brief, the
structural and biological characteristics of expressed dar-
bepoetin alfa were very similar to Aranesp which has been
normally expressed in CHO. Our data also suggest that
produced protein has potential to be developed for clinical
use.
Keywords Characterization  Darbepoetin alfa 
Leishmania tarentolae  Purification
Introduction
Biopharmaceuticals are increasingly used to treat dis-
eases such as multiple sclerosis, rheumatoid arthritis,
cancer, and anemia. The use of drugs based on
recombinant proteins for the treatment of anemia is
more safe and efficient compared to transfusion therapy.
The implementation of recombinant human erythropoi-
etin (rhEPO) in clinical practice revolutionized the
approach to the correction of anemic conditions [1, 2].
Darbepoetin alfa is a hyperglycosylated analog of EPO
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that contains two additional sialic acid containing car-
bohydrate chains. It has been designed to contain five
N-linked glycosylation sites (Asn 24, 30, 38, 83, 88).
The new carbohydrate positions have been shown to
have no interference with receptor binding or any dis-
rupting effect on the structure of protein [3]. Darbe-
poetin alfa has been approved in 2001 by the Food and
Drug Administration (FDA) for treating anemia. The
drug stimulates the bone marrow to produce more red
blood cells in patients with chronic kidney failure or
special types of cancer [4]. The relative molecular
weight of darbepoetin alfa is 40 kDa and has a longer
circulating half-life and increased in vivo bioactivity
than EPO. Due to these properties, this glycoprotein can
be administrated less frequently to attain a proper bio-
logical influence [5, 6]. Darbepoetin alfa is marked by
Amgen under the trade name Aranesp. Therapeutic
applications of darbepoetin alfa have extended interest
in improving methods for its production. Production of
this drug in CHO has generally a number of drawbacks
including low yield, high purification cost, and possi-
bility of product contamination [7, 8]. For these rea-
sons, taking advantage of an alternative expression
system capable of solving these problems is helpful.
Among Trypanomatidae family, Leishmania tarentolae
is a non-pathogenic parasite and has been developed as
a potential eukaryotic expression host for production of
recombinant biopharmaceuticals [9, 10]. L. tarentolae is
rich in glycoproteins and its glycosylation pattern is
similar to that of mammalian that includes complex-
type oligosaccharides. L. tarentolae has simple nutrient
requirements, ability for large-scale production, high
growth rate, and safety for humans. These features
make L. tarentolae interesting as an alternative to
mammalian cells for production of recombinant proteins
[11, 12]. Different recombinant pharmaceutical glyco-
proteins such as EPO [10], interferon-gamma (IFN-c)
[13], IgG [12], and many other proteins have been
produced by L. tarentolae host. In this communication,
we characterized a recombinant darbepoetin alfa
expressed by L. tarentolae expression system.
Materials and Methods
Construction of Darbepoetin Alfa Expression
Cassette
Codon-optimized darbepoetin alfa gene was synthesized
and cloned into the pGH cloning vector (BIONEER,
Korea). Codon optimization was done by the on-line pro-
gram Optimizer (http://genomes.urv.es/OPTIMIZER). The
DNA expression cassette was constructed using
components of pLEXSY_I-blecherry3 vector (Jena Bio-
science, Cat. No. EGE-1410). The synthetic gene was
amplified by polymerase chain reaction (PCR) from the
pGH plasmid. The forward and reverse primers, which
contained restriction sties in 50 terminus (underlined),
were Darbo-forward: 5
0
-ATTCTAGACGCGCCGCCG-3
0-
and Darbo-reverse: 5
0
-AGGTACCGCGGTCGCCC-3
0
. The
restriction sites in forward and reverse primers correspond
to XbaI and KpnI enzymes, respectively. PCR was per-
formed by thermal cycler (Eppendorf, Germany) under
protocol consisted of a 94 C for 5 min, 30 cycles of 94 C
for 1 min, 56 C for 1 min, 72 C for 40, and 72 C for
10 min as final extension. PCR product (503 bp) was
digested with XbaI and KpnI, and ligated into a digested
pLEXSY_I-blecherry3 expression vector. The resultant
expression construct (pLEXSYDarbo) was purified and
verified by restriction digestion and DNA sequencing.
Then, pLEXSYDarbo plasmid was digested with SwaI
restriction enzyme and the 6000 bp fragment containing
darbepoetin alfa gene was gel purified.
Production of Transgenic L. tarentolae
Leishmania tarentolae T7-TR (Jena Bioscience, Jena,
Germany) was grown as a static suspension in Brain Heart
Infusion (BHI) broth medium containing 5 lg/ml hemin,
100 lg/ml penicillin, 100 lg/ml streptomycin, and 100 lg/
ml hygromycine at pH 7.2 and 26 C. For transfection, log-
phase parasites with OD600 = 2.0 resuspended in 400 ll of
ice-cold electroporation buffer (21 mM HEPES, 137 mM
NaCl, 5 mM KCl, 0.7 mM Na2HPO4, 6 mM glucose, pH
7.5), mixed with approximately 10 lg of the linearized
expression cassette and electroporated using an Bio-Rad
Gene Pluser at 500 lF, 450 V and two pulses. The elec-
troporated promastigotes were incubated in BHI broth
medium at 26 C for 24 h without any drug. Selection of
single colonies was done by growth on solidified BHI
medium containing 100 lg/ml nourseothricin (NTC) and
100 lg/ml bleomycin [14]. To confirm the homologs
recombination integration into the odc locus of L. taren-
tolae genome, diagnostic PCRs were performed. Genomic
DNA from 2 ml of a dense culture was prepared by con-
ventional phenol/chloroform extraction. The PCR reactions
will result in a characteristic fragment for each PCR
(Table 1), which is not observed in control reactions where
the template is the genomic DNA from the wild-type
parasite.
Expression and Purification of Recombinant Protein
For secretory expression, transfected L. tarentolae cells
were grown in BHI medium supplemented with hemin,
penicillin, streptomycin, bleomycin, and NTC at 26 C as
Mol Biotechnol (2016) 58:566–572 567
123
static suspension culture in TC flasks. The T7 driven
transcription was induced with 10 lg/ml tetracycline for
72 h after inoculation. The induction was also monitored
by measurement of fluorescence at 590 nm (excitation) and
620 nm (emission) [12, 15]. To purify the recombinant
protein, concentrated supernatant of L. tarentolae culture
was applied to a Ni–NTA affinity column (Qiagen, Ger-
many) according to the manufacture’s instruction. The
column was washed with three column volumes of the
50 mM Tris–HCl buffer (pH 7.0) containing 50 mM imi-
dazole, and then, darbepoetin alfa was eluted with an elu-
tion buffer (50 mM Tris–HCl, 50 mM NaCl, 10 mM
EDTA, 500 mM imidazole, pH 7.0).
SDS Polyacrylamide Gel Electrophoresis (SDS-
PAGE) and Western Blotting
SDS-PAGE electrophoresis under reducing and non-re-
ducing conditions was performed in a 12 % gel, followed
by staining with Coomassie brilliant Blue R-250 [16].
Recombinant L. tarentolae cells were harvested from a
3-day cell culture by centrifugation at 3500 rpm for 20 min
and supernatant of the cell culture was removed and con-
centrated. The precipitated sample was dissolved in 1X
SDS-PAGE sample buffer and then boiled for 5 min.
Samples from both wild and transgenic L. tarentolae was
separated on 12 % (w/v) SDS-PAGE gel. For Western blot,
the resolved proteins were transferred to the PVDF mem-
brane using a wet blotting system and incubated with
TBST solution containing 3 % bovine serum albumin
(BSA) for overnight at 4 C. The membrane was washed
three times with TBST and reacted with anti-EPO antibody
(2 lg; rabbit polyclonal antibody to EPO; Abcam, UK) as
the first antibody for 2 h at room temperature. After three
washes, goat anti-rabbit horseradish peroxidase (HRP)–
conjugated IgG was added and incubated for 1 h at room
temperature. The band of target protein was detected using
3, 30-Diaminobezidine (DAB) and H2O2.
Isoelectric Focusing
Isoelectric focusing (IEF) was performed in a gel with a pH
gradient from 3.0 to 10.0 using GE Healthcare (Multiphor
II, MultiTemp IV, EPS 3501 XL) with the following
modes: prefocusing at a voltage of 800 V, amperage of
30 mA, and power of 25 W for 45 min; entering of pro-
teins into the gel at 600 V, 30 mA, and 25 W for 45 min;
and separation of proteins at 1600 V, 30 mA, and 25 W for
60 min. After the separation of proteins, the gel was placed
in a fixation solution containing 0.7 M trichloroacetic acid
and 0.16 M sulfosalicylic acid and incubated for 40 min at
room temperature. Then, the gel was washed in a solution
containing 8 % acetic acid and 25 % ethanol and subjected
to staining as described above.
Ultraviolet–Visible spectrum
The ultraviolet–Visible (UV–Vis) absorption spectrum was
measured from 200 to 700 nm via UV–visible spec-
trophotometer (Shimadzu 1601 PC, Japan) with cuvette
length of 1 cm at room temperature. Aranesp was also used
as positive control in spectrum analysis.
Circular Dichroism Measurement (CD)
The CD spectrum was collected with the JASCO J-820
Circular Dichroism Spectropolarimeter in phosphate buffer
saline (PBS) (10 mM, pH 7.4) containing 0.3 mg/ml of
darbepoetin alfa and Aranesp at room temperature. The
ellipticity value [h] was obtained in millidegree (mdeg)
directly from the instrument. The cell path length of 1 cm
was utilized for the range 190–260 nm. The scanning speed
was 100 nm per min. In assay, five scans were made and
the no-protein spectrum was subtracted. For a comparative
study, Aranesp was used as positive control.
Potency Test
Inbred female BALB/c mice weighting 18–22 g, and about
6–8 weeks of day were prepared from the Research and
Production Complex of Pasteur Institute of Iran, Karaj,
Iran, and housed under standardized conditions with free
access to pelleted food and tap water. Each one received
identical amount of purified darbepoetin alfa and Aranesp
(Amgen, Thousand, CA, USA) as positive control by
subcutaneous injection (5 lg/kg in 100 ll). Peripheral
blood was harvested every 24 h and hemtocrit was
Table 1 The primers used in diagnostic PCRs
Gene Primer Sequence (5
0
?3
0
) Annealing temp. (C) Amplicon size (bp)
50odc-utr1 (aprt) A1304 TCCGCCATTCATGGCTGGTG 60
50odc-utr1 (aprt) A1715 TATTCGTTGTCAGATGGCGCAC 60 1100
blecherry- 30odc A708 GGATCCACCGCATGGCCAAGTTGACCA 60
blecherry- 30odc P1510 GTGGTGCACCCATAGTAGAGGTGC 60 2700
568 Mol Biotechnol (2016) 58:566–572
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measured using a microhematocrit centrifuge and Hema-
tology Analyzer (Sysmex, Kobe, Japan).
Results
Cloning of DNA Expression Cassette into L.
tarentolae
The synthetic darbepoetin alfa gene was isolated by PCR
on the pGH plasmid. A single 503 bp band was observed
on agarose gel after electrophoresis (Fig. 1a). The obtained
PCR product was cut with XbaI and KpnI restriction
enzymes, extracted from gel and ligated into pLEXSY_I-
blecherry3 vector. The pLEXSYDarbo expression cassette
comprise XbaI/KpnI cloning site downstream from the
signal peptide of L. mexicana secreted acid phosphatase
(LMSAP) and a C-terminal His-tag for purification. The
correct gene cloning was confirmed by restriction analysis
(Fig. 1b). The recombinant plasmid was prepared in large
scale, linearized with SwaI restriction enzyme and trans-
fected into L. tarentolae T7-TR cells by electroporation.
The transfectants were selected by plating on BHI agar
medium containing 100 lg/ml hygromycin, 100 lg/ml
bleomycin, and 100 lg/ml NTC. Individual clones were
selected and transferred into culture plates and then into TC
flasks. Integration of the expression construct into the ssu
locus of recombinant cells was confirmed by PCR analysis
which generated 1.1 (Fig. 2a) and 2.7 kbp (Fig. 2b) frag-
ments. Amplificaltion of these fragments were not obtained
in genomic DNA of the wild-type parasite strains .
Expression of Recombinant Darbepoetin Alfa
The recombinant L. tarentolae expressed darbepoetin alfa
protein that was detectable by SDS-PAGE and Western
blotting. The DTT-reduced and non-reduced darbepoetin
alfa migrated at approximately 40 kD by SDS-PAGE
(Fig. 3a). Western blot method certainly confirmed that the
band which was observed in SDS-PAGE was the desired
protein (Fig. 3b). Furthermore, Western blotting revealed
that the obtained darbepoetin alfa was also homogeneous.
Analysis of Produced Darbepoetin Alfa
For further analysis, IEF was used for estimation of the
glycosylation profile of recombinant protein. According to
IEF result (Fig. 4), darbepoetin alfa contained 5 isoforms,
while Aranesp consisted of 10 isoforms. Figure 5 shows
UV–Vis spectra of darbepoetin alfa and Aranesp. As can be
found, there was not any noticeable difference in UV–Vis
spectrum of these proteins. This result primarily indicated
that darbepoetin alfa possess a structural similarity to
Aranesp. CD is a powerful tool for the analysis of sec-
ondary structures and conformation. The CD spectrum in
far UV region (190–260 nm) is related to alpha helix and
beta sheet content of a protein. Figure 6 shows the CD
spectra of darbepoetin alfa and Aranesp. As observed,
produced protein in L. tarentolae had a CD spectrum
similar to Aranesp. These data indicated that the secondary
structure of darbepoetin alfa was not altered.
Potency Result
The result of in vivo bioassay is depicted in Fig. 7. As can
be found, the content of reticulocyte increases for produced
darbepoetin alfa by L. tarentolae (22) and Aranesp was
similar.
Discussion
Darbepoetin alfa is an analog of human EPO, which has an
increased biological half-life due to the increased degree of
glycosylation when compared to that of the native EPO. It
has higher in vivo stability, and the time of its biological
half-life is three times higher than that of EPO. Because of
these properties, the use of darbepoetin alfa in medical
practice allows less frequent administration to patients
[17, 18]. It has been shown that leishmaina protozoan can
be applied as an alternative to express foreign genes with
the eukaryotic source [19]. L. tarentolae is a non-patho-
genic parasite and has been developed as a potential
eukaryotic expression host. This host is rich in
1 M 1 M
A B 
Fig. 1 a PCR amplification. Lane M DNA molecular weight marker;
Lane 1 PCR product (503 bp). b Restriction enzyme analysis. Lane M
DNA molecular weight marker; Lane 1 pLEXSYDarbo digested with
XbaI and KpnI, 503 bp band related to the insert fragment
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glycoproteins and its glycosylation pattern is similar to the
mammalian that include complex-type oligosaccharides
[20]. Additionally, it offers several advantages such as
simple nutrient requirements, ability for large-scale pro-
duction, and fast growth [9]. These features make L. tar-
entolae interesting for biotechnological applications. The
goal of this research was to characterize the produced
darbepoetin alfa from L. tarentolae T7-TR. The codon-
optimized gene was cloned into the genome of L. taren-
tolae. Expression analysis showed and confirmed the
presence of a protein band at 40 kDa. The reported
expression level for proteins in L. tarentolae is usually
varied between 0.1 and 30 mg/l. For example, the
expression level for green fluorescent protein (GFP) [9],
interferon-gamma (IFN-c) [13], and human coagulation
factor VII [21] has been achieved to be 30.0, 9.5 and 1 mg/
ml, respectively. In this study, a codon-optimized ORF was
used which resulted in 51.2 mg/ml of culture medium. This
result was more than what has been reported in CHO cell
(43.0 mg/ml) [7]. Hence, it can be concluded that the
codon optimization of target gene resulted in a good
approach to enhance protein yield. For further study, the
purified protein was also structurally characterized. Pri-
marily, the isoform composition of target protein was
A 
2 1 M
1100 bp
B 
2 1 M
2700 bp 
Fig. 2 a Diagnostic PCR with A1304 and A1715 primers. Lane M
DNA molecular weight marker; Lane 1 1.1 kbp PCR product; Lane 2
wild-type parasite b Diagnostic PCR on genomic with A708 and
P1510 primers. Lane M DNA molecular weight marker; Lane 1 2.7
kbp PCR product; Lane 2 wild-type parasite
BA
1                M 
75.0 
63.0 
40.0 
30.0 
17.0 
10.0 
M          1          2
100.0 
135.0 
kDa 
Fig. 3 Expression analysis. a SDS-PAGE. Lane M protein marker;
lane 1 purified darbepoetin alfa under non-reducing condition; Lane 2
purified darbepoetin alfa under reducing condition. b Western blot.
Lane M protein marker; lane 1 transfected cell with darbepoetin alfa
1 
pH= 3.0 (+) 
pH= 10.0 (_)
2 
Fig. 4 Isoelectrohoretic separation of isoforms. Lane 1 shows the
produced darbepoetin alfa in L. tarentolae; Lane 2 shows the drug
Aranesp
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studied (Fig. 4). The comparative drug, Aranesp, which has
been produced in CHO host contained 10 isoforms of the
protein, while darbepoetin alfa consisted of 5 isoforms. The
differences in isoform profiles between the darbepoetin alfa
from L. tarentolae and CHO represented distinct glycosy-
lation, which originated from cell lines. In other words,
expressed darbepoetin alfa was exceptionally more
homogenous than darbepoetin alfa in CHO. Similar profiles
have also been found in other LEXSY-produced protein
including IFN-c and EPO suggesting that it’s a common
feature of all recombinant glycoproteins produced in L.
tarentolae expression system (LEXSY) [9]. Based on the
further structural analysis using UV–Vis and CD spectra, it
was proven that the darbepoetin alfa from L. tarentolae had
similar structure to analogous protein expressed in CHO.
The DTT-reduced and non-reduced darbepoetin alpha
migrated approximately at the same MW by SDS-PAGE.
The obtained result was contradictory to our knowledge
that darbepoetin alpha contains two disulfide. It might be
possible that expressed protein was not properly folded
through production in L. tarentolae host. However, this
hypothesis was rejected by the CD data (Fig. 6) that target
protein had native folding and secondary structure. Previ-
ously, Breitling and coworkers reported the expression of
EPO in L. tarentolae [10]. But, no information about
reducing SDS-PAGE has been given in their paper;
therefore, we cannot compare our result with them.
Accordingly, in order to further characterize the disulfide
linkages of darbepoetin alfa, MALDI-TOF mass spec-
troscopy analysis can be carried out. Reticulocyte experi-
ment results showed that the biological activity of
recombinant darbepoetin was similar with that of Aranesp.
Fig. 5 UV–Vis absorption
spectra of darbepoetin alfa 1 and
Aranesp 2. Aranesp was used in
parallel as positive control. The
concentration of both protein
samples was 0.2 mg/ml. The
medium was phosphate buffer
saline (PBS), 10 mM, and pH
7.4
Fig. 6 CD spectra of darbepoetin alfa 1 and Aranesp 2 in the far UV
region (190–260 nm). The concentration of both protein samples was
0.3 mg/ml. The medium was phosphate buffer saline (PBS) 10 mM
and pH 7.4. Each point is the mean of four independent measure-
ments. Temperature 20 C
Fig. 7 Potency test result. Aranesp was used in parallel as positive
control
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Therefore, it can be concluded that the difference in gly-
cosylation profile did not change the potency of drug. In
summary, the results presented here demonstrate that
expressed darbepoetin alfa in L. tarentolae was structurally
similar to its original drug which has been previously
produced in CHO.
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